Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
Provided By GlobeNewswire
Last update: Oct 14, 2025
SALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has added two genes, F8 and FXN, to the Foresight® Carrier Screen Universal Plus Panel.
Read more at globenewswire.com
